Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026European Journal Of HaematologyOpen Access

KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations

View Full Paper
Ask AI
Bookmark
Share

Authors

KTKensuke TakaokaSMSarah MottRYRatdanai Yodsuwan

Discussion

Loading...

Member takes

Overview

Retrospective study assesses KRAS mutations' effect on survival in MAPK-mutated acute myeloid leukemia, suggesting prognostic significance.

Key Points

  • The aim is to evaluate the impact of KRAS and MAPK mutations on survival outcomes in newly diagnosed acute myeloid leukemia.
  • Conducted a retrospective analysis of 74 patients with newly diagnosed MAPK-mutated AML.
  • Endpoints included overall survival, complete remission following treatment, and relapse-free survival.
  • Statistical analyses were performed using logistic and Cox regression models.
  • Estimated 5-year overall survival was 28.9%.
  • KRAS mutation associated with inferior overall survival (HR: 2.14, 95% CI: 1.10–4.17).
  • Median relapse-free survival after achieving complete remission was 13.3 months.

Cite This Study

Takaoka et al. (2026) studied this question.

synapsesocial.com/papers/6a65a962d3aea3239cd79390https://doi.org/10.1111/ejh.70270
View Full Paper
Ask AI
Bookmark
Share